验证数据展示
经过测试的应用
| Positive FC detected in | HUVEC cells |
推荐稀释比
| Application | Dilution |
|---|---|
| This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
98009-1-RR targets VEGFR2/CD309 in FC applications and shows reactivity with human samples.
| Tested Applications | FC Application Description |
| Tested Reactivity | human |
| Immunogen | Recombinant protein 种属同源性预测 |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Full Name | kinase insert domain receptor (a type III receptor tyrosine kinase) |
| Synonyms | KDR, VEGFR2, VEGFR2/KDR, Protein-tyrosine kinase receptor flk-1, FLK-1 |
| Calculated Molecular Weight | 152kd |
| GenBank Accession Number | NM_002253 |
| Gene Symbol | KDR |
| Gene ID (NCBI) | 3791 |
| RRID | AB_3672151 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P35968-1 |
| Storage Buffer | PBS with 0.09% sodium azide. |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
背景介绍
VEGFR2, also named as CD309, KDR and FLK1, is a receptor for VEGF or VEGFC. VEGFR2 which belongs to the protein kinase superfamily, has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. VEGFR2 functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. Mutations of this gene are implicated in infantile capillary hemangiomas.
实验方案
| Product Specific Protocols | |
|---|---|
| FC protocol for VEGFR2/CD309 antibody 98009-1-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |